Genmab — August 2018

[gentogen]

Se punkt 3 samt linket i slutningen af det punkt (inklusionskriterier): http://www.hovon.nl/working-groups/working-groups/llpc.html

[Solsen]

Tak det prøver jeg

[peter12]

Jeg ved ikke om det er nyt at MOR202 udvikling i MM bliver stoppet ? https://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-resultshttps://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-results

[peter12]

https://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-results

[Plimsoller]

God morgen

[polle1]

God morgen

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[jkj]

jo det er nyt peter, kan måske tolkes positivt i forhold til evt. patent krængelse.

[Sukkeralf]

Det lader i hvert fald til at MorphoSys ikke længere ser nogen mulighed for partneraftale af nogen art - om der kan drages nogle konklutioner i retning af patentsagen er mere tvivlsomt, tænker jeg.

[Legolas23]

Lignede det ikke også at MOR202 blev kørt frem som et PR stunt for at argumentere for, de havde aktiviteter i MM af hensyn til retssagen?

[E_L]

EMA expects a staff loss of about 30% due to Brexit. As if they weren´t slow enough… http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/08/news_detail_002999.jsp&mid=WC0b01ac058004d5c1

[E_L]

article on Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States. https://www.ncbi.nlm.nih.gov/pubmed/?term=29290170

[E_L]

However, only the addition of DAR or PAN may be considered cost-effective options according to commonly cited thresholds

[E_L]

the article is from januari, but hey, it is Agurketid
full text https://www.jmcp.org/doi/10.18553/jmcp.2018.24.1.29

[Raffles]

Preclinical evaluation of DuoBody CD3xCD20 to be presented by Ida Hiemstra 14th November 14:35 at conference in Lisbon https://www.pegsummiteurope.com/advancing-bispecifics

[E_L]

That link hints that you are correct that the first patient may have been dosed - A clinical study evaluating the DuoBody-CD3xCD20 is currently enrolling.

[E_L]

Optimizing Early Sequencing and Treatment in MM https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/optimizing-early-sequencing-and-treatment-in-mm

[bibob]

God morgen.

[ienk1]

https://www.mpeurope.org/2018/08/02/ema-committee-gives-green-light-for-daratumumab-in-newly-diagnosed-myeloma/#more-1351